Last updated: 2026-09-15 22:17:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Arbutus Biopharma Corporation (ABUS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.06, with a market capitalization of $1.01B and a P/E ratio of 6.64. Over the past 52 weeks, its price has ranged from $3.50 to $5.45. This page covers its latest market performance, valuation, price trends and company information.
$1.01B | |
$5.11 | |
$12.60 | |
$0.82 | |
$5.13 | |
3.86M | |
3.11M | |
6.64 | |
$5.45 | |
$3.50 | |
-- | |
-- |
Arbutus Biopharma Corporation (ABUS) is trading at $5.06 in after-hours trading as of 2026-09-15 21:06:00, down 1.46% ($0.08) from the regular-session close of $5.13.
After-hours trading shows how investors are pricing ABUS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Arbutus Biopharma Corporation (ABUS) moved from $5.12 to $5.06, representing a decline of 1.19% ($0.06).
The stock traded between $5.04 and $5.23 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 3.90 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 79.9%
ABUS is currently trading at $5.06, placing it 79.9% of the way from its 52-week low of $3.50 to its 52-week high of $5.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arbutus Biopharma Corporation (ABUS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.